BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 35109664)

  • 1. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
    Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
    Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Bozzarelli S; Personeni N; Rimassa L
    Expert Opin Investig Drugs; 2022 Apr; 31(4):425-435. PubMed ID: 35152830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
    Roessler D; Ă–cal O; Philipp AB; Markwardt D; Munker S; Mayerle J; Jochheim LS; Hammer K; Lange CM; Geier A; Seidensticker M; Reiter FP; De Toni EN; Ben Khaled N
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3065-3073. PubMed ID: 35864269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
    Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
    Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
    Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
    Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.